Treatment · Experimental
Therapeutic apheresis (H.E.L.P.)
An invasive blood-filtering procedure marketed by some private clinics for long COVID, often at great expense. There is no controlled evidence that it works, and specialists urge real caution.
Short version: apheresis to remove microclots">microclots">microclots is unproven for long COVID, invasive, and often very costly. No controlled trial supports it; approach only within a registered trial.
Filtering the blood
Apheresis runs blood through a machine that removes certain components, in this case aiming to clear microclots and inflammatory factors. Private clinics have offered it for long COVID.1
What the evidence really is
There is no controlled trial showing apheresis helps long COVID. Reports are anecdotal, the procedure is invasive, and clinics often charge many thousands out of pocket. Specialists urge caution against unproven, expensive treatments.1
unproven invasive and costly
The honest position
Apheresis for long COVID is experimental and should be approached with great care, ideally only inside a registered trial. Desperation is understandable; it is also exactly what unproven, costly offerings exploit.
What we don't know
Honest about the edges of the evidence. These are open questions, not settled answers.
- Whether apheresis helps long COVID in any controlled study.
- How to protect patients from costly unproven offerings.
- Whether microclot clearance translates to symptom relief.
References
Every reference is free to read in full.